Athenex Stock News

Athenex Inc's (NASDAQ: ATNX) abstract for subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral Paclitaxel) for metastatic breast cancer has been accepted for poster presenta

Nuveen Asset Management LLC lowered its stake in shares of Athenex, Inc. (NASDAQ:ATNX) by 39.5% in the second quarter, Holdings Channel reports. The institutional investor owned 300,608 shares of the companys stock after selling 196,385 shares during the period. Nuveen Asset Management LLCs holdings in Athenex were worth $3,637,000 as of its most recent SEC []

Athenex, Inc. (NASDAQ:ATNX) saw some unusual options trading on Friday. Stock investors bought 3,516 call options on the company. This represents an increase of 833% compared to the typical daily volume of 377 call options. ATNX has been the topic of a number of research reports. Zacks Investment Research lowered Athenex from a buy rating []

Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.

Athenex, Inc. (NASDAQ:ATNX) was the recipient of some unusual options trading on Friday. Investors purchased 3,516 call options on the company. This is an increase of 833% compared to the typical volume of 377 call options. In other Athenex news, Director Jinn Wu purchased 50,000 shares of the stock in a transaction that occurred on […]

Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.

BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies f

BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development will present at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 3:55 pm ET.

BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for

Shares of Athenex, Inc. (NASDAQ:ATNX) have earned a consensus rating of Hold from the ten analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating on the company. The average 1 []

In the latest trading session, 0.81 million Athenex Inc. (NASDAQ:ATNX) shares changed hands as the companys beta touched 0.58. With the companys most recent per share price at $2.02 changed hands at -$0.08 or -4.05% at last look, the market valuation stands at $231.82M. ATNXs current price is a discount, trading about -642.57% off its Athenex Inc. (NASDAQ: ATNX): Why Investors Shouldnt Ditch ATNX Stock In 2021 Read More »

Credit Suisse AG boosted its holdings in Athenex, Inc. (NASDAQ:ATNX) by 24.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 630,044 shares of the companys stock after buying an additional 125,723 shares during the quarter. Credit Suisse AG owned approximately 0.58% of Athenex []

Boothbay Fund Management LLC acquired a new stake in shares of Athenex, Inc. (NASDAQ:ATNX) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 22,680 shares of the companys stock, valued at approximately $105,000. A number of other institutional investors and hedge funds also recently made changes to their []

Schonfeld Strategic Advisors LLC reduced its position in shares of Athenex, Inc. (NASDAQ:ATNX) by 66.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 63,918 shares of the companys stock after selling 128,090 shares during the quarter. Schonfeld Strategic Advisors LLCs holdings in Athenex were []

Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2021 Results - Earnings Call Transcript